TIANJIN, China, July 20, 2021 /PRNewswire/ — Juventas Cell Remedy Ltd., a Chinese language biopharmaceutical firm introduced the shut of a $60 million+ Collection C financing led by CICC Capital and Oceanpine Capital. The co-investors embody Delian Capital and current traders similar to Jiadao Personal Capital, Redhill Capital, Tianjin Enterprise Capital, Dalton Capital, and RFUND. Firstly, Juventas Cell Remedy Ltd. (hereinafter known as Juventas) plans to make use of the raised fund to advance the CD19 CAR-T candidate CNCT19 into commercialization and its world market growth, secondly, with the CAR expertise, iPSCs expertise, and gene-editing expertise platforms, the autologous and common/allogeneic/off-the-shelf merchandise protecting hematologic tumor and stable tumor remedy within the firm’s pipeline shall be all significantly fueled and propelled.
“We’re grateful for the assist from our current and new traders. Juventas constantly appreciates and virtually explores technological innovation in cell and gene remedy realm. Guided by our “Fast Commercialization and Internationalization” growth technique, we keep in-depth cooperation with nationwide first-class tutorial institutes and hospitals, assemble sustainable worldwide research-development-innovation platforms for potential merchandise, and function worldwide aggressive pipeline whereas activating the correspondent scientific trials and commercialization course of,” stated Lv Lulu, Ph.D., the CEO of Juventas, “for Juventas’ purpose is to supply extra sufferers with secure, efficient, and accessible cell remedy merchandise.”
“Immune cell remedy shall be one of many dominating approaches for the remedy of oncology sooner or later, though the brand new drug growth and commercialization of cell remedy merchandise will be difficult, the applying panorama remains to be exceptionally promising.”. Zhao Xinhao, the challenge chief of CICC Capital launched, “Juventas has a core staff specializing in R&D-production-sales entire industrial chain in cell remedy realm. By cooperating with China’s high analysis institutes and advancing the candidates to commercialization and internationalization with the revolutionary medicine industrial mindset, Juventas has turn into one of many main corporations within the Chinese language cell immunotherapy enterprise. Its core product with unbiased mental property rights, CNCT19, is originated from China. In Dec. 2020, CNCT19 was granted the “Breakthrough Remedy Designation (BTD)” by the Nationwide Medical Merchandise Administration (NMPA). CNCT 19 is extremely anticipated to be the primary CD19 CAR-T product with China’s unbiased mental property rights that enters each Chinese language and worldwide markets. In the meantime, one of many indications is acute lymphoblastic leukemia for adults, which has no marketed CAR-T merchandise globally to date, is anticipated to obtain NDA (New Drug Software) approval and produce advantages for sufferers. CICC Capital is delighted to share sustainable industrial assets with Juventas, and collectively increase the event of the corporate and the cell immunotherapy trade.”
Mr. Chen Liguang, the managing companion of Oceanpine Capital underlines, “the demand progress in biomedicine market is unremitting. Naturally, innovation and internationalization would be the mainstream of China’s new drug growth mechanism. Immune cell remedy medicine, as one of many representatives of Chinese language revolutionary medicine, is of nice worth for long-term funding. We sincerely cherish and respect the R&D innovation and fast commercialization functionality of Juventas. The partnership between us will fulfill the medical wants of the tumor market domestically and internationally. Additionally, I imagine this cooperation shall be an engine to take care of the main place of Juventas within the realm of cell remedy.”
About Juventas Cell Remedy Ltd.
Based in June 2018, Juventas Cell Remedy Ltd. is a next-generation biopharmaceutical firm pushed by cell and gene revolutionary applied sciences. Juventas established an revolutionary worldwide new drug R&D system with CAR expertise, iPSCs expertise, and gene-editing expertise platform as substratum and core to develop the worldwide aggressive pipeline. Juventas builds profound cooperation with China’s main hospitals and scientific analysis institutes and is dedicated to establishing a preeminent platform for cell remedy product R&D, and commercialization.
CNCT19, a CD19-targeted chimeric antigen receptor (CAR) T-cell remedy, is the primary core product of Juventas, which is derived from the long-term revolutionary expertise accumulation of the Institute of Hematology and Blood Illnesses Hospital, Chinese language Academy of Medical Sciences. On 29 Nov. 2019, Nationwide Medical Merchandise Administration (NMPA) has cleared its Investigational New Drug (IND) utility for Juventas’ CNCT19, and the correspondent indications are relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL). At the moment, the Section II scientific trials of CNCT19 (for each ALL and NHL) are in progress. In Dec. 2020, CNCT19 was granted the “Breakthrough Remedy Designation (BTD)” by the Nationwide Medical Merchandise Administration (NMPA). CNCT 19 is extremely anticipated to be the primary CD19 CAR-T product with China’s unbiased mental property rights that enters each Chinese language and worldwide markets.
Juventas regards sufferers’ unmet scientific wants because the guiding star. By way of strict cell remedy drug manufacturing and high quality management system, each member of Juventas is decided to supply extra sufferers with secure, efficient, and accessible cell remedy merchandise. On the similar time, Juventas constantly establishes an revolutionary and sustainable pipeline that covers hematologic tumors, stable tumors, and pioneering common merchandise. Furthermore, the corporate possesses the world’s main R&D expertise platform, CMC platform, QC platform, and bases for commercialization manufacturing. As for Juventas’ services for manufacturing and R&D in China, there’s a 2000m2 R&D middle in Beijing, and a virtually 10000m2 GMP manufacturing base in Tianjin.
SOURCE Juventas Cell Remedy Ltd.